Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines
- PMID: 7808004
Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines
Abstract
We have examined the effects of antisense oligomers (AOs) of various lengths, sequences and chemistry on the proliferation of eight different cell lines, five derived from patients with chronic myelogenous leukemia (CML) and three from other sources. In general, phosphodiester AOs were inactive, presumably due to degradation by nucleases present in fetal calf serum. Both BA2 and B3A2 phosphorothiolate AOs (but not corresponding sense oligomers) significantly inhibited the proliferation of three CML cell lines (BV173, LAMA84, and KYO1), but the effect was independent of the type of breakpoint expressed by each cell line, suggesting that the inhibition was sequence dependent but not sequence specific. The CML cell lines tested showed different sensitivities to inhibition of proliferation by AOs--lines with defective expression of the normal ABL protooncogene (e.g. BV173) were more readily inhibited than lines with a normal ABL message (e.g. K562). We conclude that further studies are necessary to delineate the precise mechanism(s) by which CML cell proliferation is inhibited by AOs.
Similar articles
-
Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.Exp Hematol. 1995 Dec;23(14):1606-11. Exp Hematol. 1995. PMID: 8542954
-
Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.Leukemia. 1994 Jan;8(1):129-40. Leukemia. 1994. PMID: 8289478
-
Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.Leukemia. 1995 Jan;9(1):118-30. Leukemia. 1995. PMID: 7845006
-
Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.Stem Cells. 1993 Oct;11 Suppl 3:89-95. doi: 10.1002/stem.5530110921. Stem Cells. 1993. PMID: 8298481 Review.
-
Inhibition of P210 expression in chronic myeloid leukaemia: oligonucleotides and/or transduced antisense sequences.Leuk Lymphoma. 1993;11 Suppl 1:139-43. doi: 10.3109/10428199309047877. Leuk Lymphoma. 1993. PMID: 8251887 Review.
Cited by
-
Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.Nucleic Acids Res. 1998 Apr 1;26(7):1567-75. doi: 10.1093/nar/26.7.1567. Nucleic Acids Res. 1998. PMID: 9512525 Free PMC article.
-
Autografting as first line treatment for chronic myeloid leukaemia.J Clin Pathol. 1998 Feb;51(2):92-5. doi: 10.1136/jcp.51.2.92. J Clin Pathol. 1998. PMID: 9602679 Free PMC article. Review.
-
Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells.Mol Med. 1999 Oct;5(10):693-700. Mol Med. 1999. PMID: 10602778 Free PMC article.
-
Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.Mol Med. 1996 Jul;2(4):429-38. Mol Med. 1996. PMID: 8827713 Free PMC article.
-
Antisense approaches to the gene therapy of cancer--'Recnac'.Cancer Metastasis Rev. 1996 Sep;15(3):287-99. doi: 10.1007/BF00046343. Cancer Metastasis Rev. 1996. PMID: 9034592 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous